Efficacy and safety of Osimertinib in patients with EGFR T790M positive advanced Non small cell lung cancer (NSCLC) from a French temporary authorization for use (ATU) program

Trial Profile

Efficacy and safety of Osimertinib in patients with EGFR T790M positive advanced Non small cell lung cancer (NSCLC) from a French temporary authorization for use (ATU) program

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2016 New trial record
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top